TabWrap Deal

RNS Number:7808D
BioProgress PLC
13 September 2007


For Immediate Release                                         13 September 2007


                                BioProgress plc

                      New Commercial Partner for TabWrapTM


London UK, 13th September 2007, BioProgress plc (AIM: BPRG) ("BioProgress" or
the "Company"), the specialty pharmaceutical and healthcare company has
announced a commercial partner for its core enabling technology, TabWrapTM.
BioProgress has entered into agreements with Barr-Pliva, a leading global
generics and specialty Pharma company, to partner and co-promote certain
products using the Company's TabWrapTM enabling system in agreed territories.

TabWrapTM is a unique method of dry coating novel tablet cores. The technology
is being applied initially into the analgesic category of medicines with
products already within its development pipeline. The total value of the
products on a global basis has the potential of generating revenues in excess of
$100 million.

Graham Fraser-Pye, Managing Director Barr-Pliva UK, said "We are pleased to be
working with BioProgress with products where we can offer our considerable sales
and marketing skill base. We see this as a long term working relationship with
the opportunity for multiple products."

Steve Martin, Chief Development Officer, BioProgress said: "The agreement with
Barr-Pliva is an important step once again demonstrating the commercial value of
TabWrapTM with a confirmed product. The relationship is strong and we expect to
enhance our relationship over the coming months with additional products and
technologies."

Richard Trevillion, Chief Executive Officer, BioProgress said: "Barr-Pliva is a
tremendous partner for the Group capable of achieving rapid adoption of our
unique products. We are very pleased to be working with Graham and his team."


For further information:

BioProgress Plc                                   + 44 (0) 20 7098 9881
Richard Trevillion, CEO

Steve Martin, CDO

Hiral Patel, CFO

Buchanan Communications                           + 44 (0) 20 7466 5000
Rebecca Skye Dietrich/Mark Court


About BioProgress

BioProgress plc is an innovative specialty pharmaceutical and healthcare
business based around its platform technologies in polymer and film systems.
Listed on London's AIM in May 2003, The Company has over 80 patents granted or
in application within 24 patent families and has product development agreements
and strategic alliances with several global companies. As a virtually integrated
business, BioProgress has acquired sales and marketing resources within Europe
and the US as a launch mechanism for its own pharmaceutical products. The
business continues to develop innovative delivery mechanisms using its XGELTM
polymer technology. For further information please go to www.bioprogress.com


Forward-Looking Information

The Ordinary Shares of BioProgress plc are registered under the US Securities
and Exchange Act of 1934.  To the extent that this announcement contains certain
"forward-looking statements" within the meaning of the Private Securities
Litigation Reform Act of 1995, this paragraph applies.  These statements are
based on management's current expectations and are subject to uncertainty and
changes in circumstances.  Actual results may vary materially from the
expectations contained in the forward-looking statements.  The forward-looking
statements in this release include statements addressing future financial and
operating results and the timing and benefits of the reorganisation.  Detailed
information about factors pertinent to the business of the company that could
cause actual results to differ is set forth in the Company's filings with the
Securities and Exchange Commission.  The Company is under no obligation to (and
expressly disclaim any such obligation to) update or alter its forward-looking
statements whether as a result of new information, future events or otherwise.
This announcement is for information only and does not constitute an offer or
invitation to acquire or dispose of any securities or investment advice.  The
distribution of the announcement and/or issue of securities in certain
jurisdictions may be restricted by law.  Persons into whose possession this
announcement comes are required to inform themselves about and to observe such
restrictions.



                      This information is provided by RNS
            The company news service from the London Stock Exchange

END
MSCZGGMLZZDGNZZ